Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 25: Cardiac Biomarker Analysis from the EARLY TAVR Trial
Author(s): Brian Lindman Added: 7 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in… View more

Vascular Disease and Surgery
Advances in Cardioprotection Strategies: Focusing on Breast Cancer and Beyond Through Novel Biomarkers and Pharmacological Approaches
Author(s): Giulia Tamburrini , Celia de Cobos García , Teresa López Fernández Added: 2 months ago

CV Disease in Special Populations

Heart Failure
ESC HF 25: The FIVE-STAR Trial
Author(s): Added: 6 months ago
ESC HF 25 - FIVE-STAR primary outcome is neutral, though finerenone was shown to significantly reduce UACR rates with a 29% greater reduction compared to placebo.We are joined by Dr Atsushi Tanaka (Saga University, Saga, JP) to discuss the findings from FIVE-STAR, a randomized trial investigating the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2… View more

Cardiovascular Renal Metabolic
Riccardo Inciardi headshot
Research Area(s) / Expertise:

Heart Failure

Echocardiography & Ultrasound

 Job title: Medical Doctor, Cardiologist
Riccardo M. Inciardi is currently Assistant Professor and Consultant in Heart Failure and Echocardiography at the Division of Cardiology at the University Hospital of Brescia (Italy). He is Affiliated to Research at the Center for Heart Failure and Arrhythmia at the Karolinska Institutet (Sweden). Over the last few years, he obtained the PhD Degree in Clinical and Experimental Biomedical Science… View more
HFSA 25: 96-week Analysis from FOREST-HCM
Author(s): Ahmad Masri Added: 1 month ago
HFSA 25 - Aficamten found to significantly improve NYHA and KCCQ-CSS scores in new 96-week data from FOREST-HCM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss findings from the FOREST-HCM trial, examining the sustained safety and efficacy of aficamten in patients with symptomatic nonobstructive hypertrophic cardiomyopathy.This phase 2 open-label study followed 34… View more

Heart Failure
AHA 25: MAPLE-HCM Responder Analysis
Author(s): Andrew Wang Added: 1 week ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive… View more

Heart Failure
Job title: Associate Director of Medical and Scientific Affairs
Hans-Peter Brunner-La Rocca
Research Area(s) / Expertise:
Hans-Peter Brunner-La Rocca is a heart failure cardiologist, trained in Switzerland and has been working in the Academic Hospital Maastricht, in the Netherlands for 10 years. He is head of the Heart Failure Clinic and head of the division of Structural Heart Diseases. His main research interests are biomarkers and eHealth to achieve personalised treatment in heart failure. He was the trial leader… View more
Research Area(s) / Expertise: Job title: Professor of Medicine
Dr Eileen O’Meara is Professor at the Department of Medicine at the University of Montrealand practices cardiology at the Montreal Heart Institute. Dr O’Meara pursued a Fellowship in Heart Failure at the Western Infirmary & Glasgow Royal Infirmary in the UK, and another in Stress Echocardiography and Tissue Doppler at Hôpital Européen Georges Pompidou in Paris. Her research focuses on… View more